Julian A. Torres Isasiga
<p>Dr. Torres completed his MD degree at Universidad del Valle (Cali, Colombia) in 2006. He then joined the International Center for Training and Medical Research (CIDEIM) in his home town, Cali, where he spent almost 3 years as a research assistant in the area of Gram negative Bacterial Resistance, where he published and presented his work in national and international journals and conferences.</p>
<p>After completing his Internal Medicine residency at Jacobi Medical Center in the Bronx, Dr. Torres completed his fellowship in Infectious Diseases at New York University (NYU). He then joined Englewood Hospital where he spent more than 2 years as an Infectious Disease consultant.</p>
<p>Dr. Torres joined Montefiore Medical Center/Albert Einstein College of Medicine in 2017 as an Assistant Professor. Since then, he has been providing PrEP, PEP, STI, HCV and HIV care to patients in the Bronx, as well as inpatient Infectious Disease consultation services at the hospital. He has an interest to expand HIV prevention projects in Colombia and is working closely with Corporacion de Lucha contra el SIDA in Cali.</p>
<p>Dr. Torres has been a member of the Infectious Disease Society of America since 2012.</p>
<p> </p>
<p> </p>
<p align="left"><strong><span style="font-family: Times New Roman; font-size: medium;">Selected Publications</span></strong><strong><span style="text-decoration: underline;"><span style="font-family: Times New Roman; font-size: medium;"><br /></span></span></strong></p>
<p class="MsoListParagraph" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span lang="ES" style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;">Nori P, Szymczak W, Puius J, Sharma A, Cowman K, Fleischner Z, Bartash R, Chen V, Corpuz M, Gialanella P, Alpert P, Felsen U,<strong> Torres-Isasiga J</strong>, Guo Y. </span><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US;">Emerging Co-Pathogens: New Delhi Metallo-beta-lactamase producing Enterobacterales Infections in New York City COVID-19 Patients. </span><span lang="ES" style="color: black; mso-color-alt: windowtext;">Int J Antimicrob Agents. 56(6):106179. doi: 10.1016/j.ijantimicag.2020.106179. Epub 2020 Sep 25.<strong> (2020)</strong></span></p>
<p class="MsoListParagraph" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span lang="ES" style="color: black; mso-color-alt: windowtext; mso-bidi-font-weight: bold;">Mueses-Marín HF, Alvarado-Llano B, </span><strong style="mso-bidi-font-weight: normal;"><span lang="ES" style="color: black; mso-color-alt: windowtext;">Torres-Isasiga J</span></strong><span lang="ES" style="color: black; mso-color-alt: windowtext; mso-bidi-font-weight: bold;">, Camargo-Plazas P, Bolívar-Rocha MC, Galindo-Orrego X, Martínez-Cajas JL. </span><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;">Scales to Assess Knowledge, Motivation, and Self-Efficacy for HIV PrEP in Colombian MSM: PrEP-COL Study. AIDS Research and Treatment, vol. 2021, Article ID 4789971, 11 pages </span><strong style="mso-bidi-font-weight: normal;"><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US;">(2021)</span></strong></p>
<p class="MsoListParagraph" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span lang="ES" style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;">Falsey AR, et al., </span><strong style="mso-bidi-font-weight: normal;"><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US;">and the AstraZeneca AZD1222 Clinical Study Group (Julian A. Torres). </span></strong><span lang="ES" style="color: black; mso-color-alt: windowtext;"><a href="https://pubmed.ncbi.nlm.nih.gov/34587382/"><span lang="EN-US" style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold; text-decoration: none; text-underline: none;">Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine</span></a></span><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;">. </span><span lang="ES" style="color: black; mso-color-alt: windowtext; mso-bidi-font-weight: bold;">N Engl J Med. </span><span lang="ES" style="font-size: 10.5pt; font-family: 'Segoe UI',sans-serif; color: #4d8055; background: white;"> </span><span lang="ES" style="color: black; mso-color-alt: windowtext; mso-bidi-font-weight: bold;">doi: 10.1056/NEJMoa21052902021. </span><strong style="mso-bidi-font-weight: normal;"><span lang="ES" style="color: black; mso-color-alt: windowtext;">(2021).</span></strong></p>
<p class="MsoListParagraph" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span lang="ES" style="color: black; mso-color-alt: windowtext; mso-bidi-font-weight: bold;">Martínez-Cajas J, Alvarado-Llano B, Martínez-Buitrago E, <strong>Torres-Isasiga J</strong>, Arrivillaga M, Camargo P, Galindo-Orrego X, Mueses-Marín H. </span><span lang="ES" style="color: black; mso-color-alt: windowtext;"><a href="https://pubmed.ncbi.nlm.nih.gov/35067114/"><span lang="EN-US" style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold; text-decoration: none; text-underline: none;">AC-2020-12-1420.R1 - HIV care providers' familiarity, concerns, and attitudes about HIV PrEP in Colombia: insights from the PrEP-Col-Study.</span></a></span><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;"> AIDS Care. doi: 10.1080/09540121.2022.2029813 </span><strong style="mso-bidi-font-weight: normal;"><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US;">(2022)</span></strong></p>
<p class="MsoListParagraph" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span lang="ES" style="color: black; mso-color-alt: windowtext; mso-bidi-font-weight: bold;">Martínez-Cajas JL, <strong>Torres J, </strong>Mueses HF, Camargo Plazas P, Arrivillaga M, Gomez SA, Galindo X, Martínez Buitrago E, Alvarado-Llano BE. </span><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;">Applying Implementation Science Frameworks to Identify Factors that Influence the Intention of Healthcare Providers to Offer PrEP Care and Advocate for PrEP in HIV Clinics in Colombia: A Cross-Sectional Study. Implement Sci Commun. Mar 16; 3(1):31. doi.org/10.1186/s43058-022-00278-2 </span><strong style="mso-bidi-font-weight: normal;"><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US;">(2022)</span></strong></p>
<p class="MsoListParagraph" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span lang="ES" style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="color: black; mso-color-alt: windowtext; mso-ansi-language: EN-US;">Meyerowitz EA, Bernardo, RM, Collins-Ogle, MD, Mamber Czeresnia, J, Morales Matos, C, Mullis C, Root, H; <strong>Torres-Isasiga JA</strong>, Tsai, H; Zingman, B. Navigating HIV Screening Recommendations for People on PrEP and the Need to Update Testing Algorithms. </span><em><span lang="ES" style="color: black; mso-color-alt: windowtext;">Open Forum Infectious Diseases</span></em><span lang="ES" style="color: black; mso-color-alt: windowtext;">, ofac191. <a href="https://doi.org/10.1093/ofid/ofac191"><span style="color: black; mso-color-alt: windowtext; text-decoration: none; text-underline: none;">doi.org/10.1093/ofid/ofac191</span></a> <strong>(2022)</strong></span></p>
<p class="MsoListParagraph" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span lang="ES" style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span lang="ES-CO" style="color: black; mso-color-alt: windowtext; mso-ansi-language: ES-CO;">Arrivillaga M, Gómez SA, Mueses HF, Alvarado B, Martínez Buitrago E, Camargo-Plazas P, Hurtado LR, Bolívar MC, Galindo X, <strong>Torres J</strong>, Cajas-Martínez JL. Facilitadores y recomendaciones de proveedores de salud para la implementación de la Profilaxis Pre-Exposición en clínicas de VIH en Colombia. “Estudio PPrE-Colombia”. Rev Gerenc Polit Salud;21. </span><span lang="ES" style="color: black; mso-color-alt: windowtext;"><a href="https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fdoi.o…; target="_blank" rel="noopener"><span lang="ES-CO" style="color: black; mso-color-alt: windowtext; mso-ansi-language: ES-CO; text-decoration: none; text-underline: none;">https://doi.org/10.11144/Javeriana.rgps21.frps</span></a></span><span lang="ES-CO" style="color: black; mso-color-alt: windowtext; mso-ansi-language: ES-CO;"> <strong>(2022)</strong></span></p>
<p class="MsoListParagraph" style="margin-left: 0.5in; text-indent: -0.25in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><!-- [if !supportLists]--><span lang="ES-CO" style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: ES-CO;">·<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';"> </span></span><!--[endif]--><span lang="ES-CO">Meyerowitz EA, Gendlina I, Desai VJ, Grossberg R, Nair SR, Pujar B, Riska PF, Root HB, Toro J, <strong>Torres JA</strong>, Pirofski LA, Zingman BS. Anorectal Testing for Monkeypox Virus Infection in Men who have Sex with Men with and without Proctitis. Clin Infect Dis. 2022 Oct 13:ciac825. doi: 10.1093/cid/ciac825. Epub ahead of print. PMID: 36227656 <strong>(2022)</strong></span></p>
<p>Julian A. Torres lsasiga, MD, is an attending physician at Montefiore Einstein and Associate Professor, Infectious Diseases at our Albert Einstein College of Medicine. Dr. Torres’s clinical focus centers on general infectious disease care, HIV prevention and care, sexually transmitted infections and medical education.</p><p>After earning his Doctor of Medicine at the Universidad del Valle/Hospital Universitario del Valle in Cali, Colombia in 2006, Dr. Torres became a research assistant at the International Center for Medical Research and Training (CIDEIM) in Cali, Colombia, from 2007 to 2009. He then moved to the United States to continue his medical training, completing his internal medicine residency at Jacobi Medical Center in 2012 and an infectious disease fellowship at New York University in 2014.</p><p>Building on his clinical focus, Dr. Torres’s research is focused on HIV prevention and pre-exposure prophylaxis (PrEP). He has been co-investigator, principal investigator and sub-investigator on several research projects and he has shared his work through many national and international invited presentations and poster presentations. Dr. Torres is a reviewer for <em>Clinical Infectious Disease, Open Forum Infectious Disease</em> and the <em>International Journal of STD & AIDS</em>. His work has been published in numerous peer-reviewed journals, books, chapters, review articles and abstracts.</p><p>Dr. Torres is board certified in Internal Medicine and Infectious Disease by the American Board of Internal Medicine. He is a member of the Infectious Disease Society of America. In 2023, he received the Excellence in Teaching Award from the Division of Infectious Disease at Montefiore Einstein. The same year, Dr. Torres received the Teaching Star-Teaching Commendation Letter for the 2022-2023 Academic Year from Montefiore Einstein.</p>